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Introduction
The development of the mammary gland largely occurs
postnatally. Initially, the ductal system begins to develop
from the nipple, and is characterized by specialized struc-
tures — the terminal end buds (TEBs) — capping the end of
the ducts. TEBs grow out across the fat pad and, by bifur-
cation, lay down by puberty the minimally branched struc-
ture that covers the fat pad, at which point the TEBs
disappear. Throughout the estrus cycle there is modest
development of the ductal system, but it is during preg-
nancy that a dramatic outgrowth of secondary branches
occurs that, together with the formation of the lobuloalveolar
structures, results in the milk-producing gland. Once
weaning has occurred, this fully developed structure
regresses to a virgin-like state.
It has been well established that these events are under the
control of a complex interplay of circulating hormones, par-
ticularly estrogen, progesterone, glucocorticoids and pro-
lactin gene family members [1]. However, it has also
become clear that local mesenchymal–epithelial interac-
tions are essential for mammary development, and that
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The mammary gland undergoes morphogenesis through the entire reproductive life of mammals. In
mice, ductal outgrowth from the nipple across the fat pad results in an intricate, well spaced ductal tree
that further ramifies and develops alveolar structures during pregnancy. Ductal morphogenesis is
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the mammary gland. These data suggest that these two growth factors have complementary roles in
promoting mammary ductal morphogenesis and in maintaining ductal spacing. In addition, TGF-b3
triggers apoptosis in the alveolar epithelia, which is a necessary component of mammary gland
involution and return of the ductal structure to a virgin-like state after lactation.
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many of these are mediated by growth factors that are often
synthesized in response to the circulating hormones. These
include wnt family proteins, TGF-a, fibroblast growth
factors, insulin-like growth factors, epidermal growth factor
[2], colony stimulating factor-1 [3], and — the subjects of the
present review — the TGF-b family of proteins and HGF/SF.
Transforming growth factor-b b isoforms
The three classical members of the TGF-b family belong to
a much larger family. In humans this family contains almost
30 members, including bone morphogenic proteins,
activins, and Mullerian inhibiting substance [4]. These
TGF-b family members have profound effects during
development, regulating cell fate by affecting proliferation,
differentiation and cell death, and therefore they are impor-
tant for the development of many tissues.
All three of the classical TGF-b isoforms (TGF-bs) activate
intracellular responses by binding to and heterodimerizing
the same two transmembrane serine/threonine kinases
(Fig. 1) [5]. In this complex the type II receptor phosphory-
lates the type I receptor (also known as activin receptor-like
kinase), activation of which results in propagation of the
signal intracytoplasmically to the transcription machinery.
This propagation is via the direct phosphorylation of SMAD
proteins [6]. Eight SMAD family members have been docu-
mented. In the case of TGF-bs, however, SMAD-2 and
SMAD-3 (or receptor phosphorylated SMADs) are the pos-
itive signaling SMADs. These phosphorylated SMADs het-
erodimerize with a common shared partner, SMAD-4. After
this they translocate to the nucleus where, by recruitment
of coactivator proteins, they participate in the transcrip-
tional activation of target genes. In contrast, SMAD-6 and
SMAD-7 are negative regulators. SMAD-7 binds to the
TGF-b-activated receptor, where it inhibits the phosphory-
lation of SMAD-2 and SMAD-3, consequently downregu-
lating the signaling pathway. SMAD-7 expression is also
upregulated by TGF-b1, allowing it to act in an autoin-
hibitory feedback loop that shuts off TGF-b signaling. Neg-
ative control also occurs by degradation of SMADs
following their ubiquinylation by SMURF-1 [5].
There is also growing evidence for other postreceptor sig-
naling pathways (probably involving the mitogen-activated
protein kinase pathway) and for other cell-type specific
TGF-b receptors [6]. Furthermore, several intracellular sig-
Figure 1
Schematic of the TGF-b signaling pathway, showing the activation cascade and points of inhibition (^). Active TGF-b, released from the latent
complex by the action of thrombospondin, binds to the type II receptor, resulting in the formation of an active receptor–signaling complex. This
binding is enhanced by accessory receptors, whereas the receptor dimerization can be inhibited by membrane-bound inhibitors such as bone
morphogenic protein and activin membrane bound inhibitor (BAMBI). After ligand binding, the receptor SMADs are phosphorylated, dimerize with
SMAD-4, and translocate to the nucleus where they recruit appropriate cofactors and coactivators to stimulate transcription of target genes. TGF-b
signaling can be blocked by the inhibitory SMADs, SMAD-6 and SMAD-7, which prevent receptor–SMAD activation; and by the ras pathway,
which can lead to inhibition of nuclear translocation of the dimeric SMAD complex. Receptor SMADs can also be degraded following
ubiquinylation by the ubiquitin ligase SMURF1. Figure adapted from Massagué [5]. Breast Cancer Research    Vol 3 No 4 Pollard
naling pathways interact with the TGF-b signaling pathway
to ensure cell-type specific responses through activation
of different genes. Discussion of this aspect of TGF-b
biology is beyond the scope of the present review, and the
reader is referred to the several recent excellent reviews
on this topic [4,5,7].
In order to understand the roles of TGF-b in vivo, it is also
important to appreciate that there are several extracellular
controls on TGF-b function that can spatially and temporally
regulate TGF-b action to allow context dependent action
(Fig. 1). Most significantly, TGF-bs are synthesized as latent
inactive precursors of transforming growth factor (LTGF)-b,
consisting of the 24-kDa cytokine and a 80-kDa dimer of the
prepro region called the latency-associated protein. During
secretion of TGF-bs from the cell the latency-associated
protein region is cleaved from the precursor molecule by
Furin-mediated proteolysis, followed by a noncovalent
attachment to the dimeric TGF-b. In nontransformed cells,
LTGF-b is covalently bound to LTGF-b binding proteins (of
which four distinct ones have been described) and
deposited in the extracellular matrix. LTGF-b is inactive, and
therefore activation is a key mechanism in the action of TGF-
b; this activation is stimulated by proteases, with the majority
of in vivo activation ascribed to thrombospondin-1 [8]. In
addition to the availability of active TGF-b, its signaling is also
regulated by membrane anchored coreceptors such as b-
glycan (also called TGF-b type III receptor), endoglin and
crypto, which potentiate the binding of TGF-b to its receptor.
Thus, in vivo, a complex web of interacting proteins exerts
both negative and positive controls over the action of TGF-b.
Transforming growth factor-b b isoforms in the
mammary gland
Expression patterns of transforming growth factor-b b
isoforms in the mammary gland
In the mammary gland TGF-bs are expressed in a complex
and overlapping pattern [9], suggesting important roles for
them in its development. All three TGF-bs are expressed in
the epithelium of the TEBs, although TGF-b2 has a very
low expression at this stage, and throughout the rest of
ductal development. In most ductal areas, expressions of
TGF-b1 and TGF-b3 are overlapping. However, TGF-b1 is
found uniquely at the tips of the developing bud, whereas
TGF-b3 transcripts are found in the flanking region.
These patterns of mRNA expression are largely recapitulated
by protein expression, although most studies did not distin-
guish active from latent TGF-bs. Preliminary studies were
conducted by Barcellos-Hoff and Ewan [10], who used anti-
bodies that can discriminate active from latent TGF-b1; those
investigators showed mosaic expression of active and inac-
tive TGF-b1 in the mammary epithelium, whereas only LTGF-b
was found in the stroma. TGF-b3 expression was also found
uniquely in the myoepithelial cells, whereas TGF-b1 was
deposited in the stroma around quiescent terminal ducts.
During pregnancy, TGF-b1 is expressed at low levels in
alveolar and ductal structures, whereas TGF-b2 has a
lower but similar pattern of expression. TGF-b3 is the most
strongly expressed of all the isoforms in the alveolar and
ductal structures. Toward the end of pregnancy and
during lactation, all isoforms are heavily downregulated
[9]. On weaning, however, TGF-b3 mRNA and protein is
dramatically upregulated in the alveolar epithelial and
ductal cells [11,12].
TGF-b receptor II expression is found in the ductal epithe-
lial and surrounding stromal cells in virgin, pregnant, and
involuting mammary gland. Similarly, in situ hybridization
localized TGF-b receptor I (activin receptor-like kinase 5)
to the same cells at all these stages of development [13],
suggesting that both epithelial and mesenchymal cells can
respond to endogenous TGF-b.
Modes of action of transforming growth factor-b b
isoforms in the mammary gland
Experiments that have introduced TGF-bs into the
mammary gland by implantation or via transgenic means
have largely suggested that TGF-b1 is a growth inhibitor,
suppressing ductal morphogenesis (Table 1). The first
experiments of this type employed the implantation of slow-
release pellets containing TGF-bs into the mammary fat
pad [14]. All three TGF-b isoforms suppressed TEB forma-
tion (in a reversible manner), causing the ends of the ducts
to take on the appearance of growth-quiescent ducts [9].
Expression of constitutively active TGF-b1 from the mouse
mammary tumor virus (MMTV) promoter resulted in a
hypoplastic ductal tree, but with no effect on lobuloalveolar
development [15]. In contrast, TGF-b1 expressed from the
later acting whey acidic protein promoter inhibited alveolar,
but not ductal development during pregnancy [16]. This
was associated with a reduction in the stem cell pool avail-
able for lobuloalveolar development [17].
More recently transgenic techniques have been employed
to express dominant-negative forms of the TGF-b recep-
tor, which are aimed at inhibition of all TGF-b isoform sig-
naling in the mammary gland. Expression of such a
dominant-negative construct in the mammary epithelium
from the MMTV promoter resulted in precocious alveolar
hyperplasia in virgin mice, but without any effect on TEB
formation [18]. Expression of the same construct primarily
in mammary stromal cells, however, caused an increase in
lateral branching, suggesting that these stromal cells were
the primary sites of action of epithelial expressed TGF-bs
[13]. This is consistent with observations that TGF-b1
slow-release implants in cleared fat pads suppressed the
formation of new end buds in transplanted mammary
epithelium [19]. Together, these experiments are in line
with roles for TGF-b1 and TGF-b3 in the maintenance of
ductal spacing by inhibition of lateral branching through
epithelial–mesenchymal signaling (Fig. 2).Insights gained from transforming growth factor-b b gene
knockout mice
Considerable insights into biologic processes have been
gained by the generation of null mutations in mice
(Table 1). All three TGF-b genes have been mutated, as
have their receptors, several SMAD genes, and LTGF-b
binding proteins [20]. Generally, these experiments were
uninformative regarding mammary development. Perhaps
the greatest insights might have come from targeted abla-
tion of the SMAD genes. Unfortunately, SMAD-4- and
SMAD-2-null mutant mice die very early in gestation, pre-
cluding mammary gland studies. However, SMAD-3–/–
mice survive up to eight weeks of age. Detailed analysis of
mammary development has yet to be reported [20],
although a preliminary analysis [21] suggested that the
mammary glands are under-developed.
The TGF-b1-null phenotype is variable, with many mice
dying during embryogenesis due to vasculature defects,
although in some cases they die within a few days of life
because of multifocal inflammatory lesions. However,
these mice can be maintained if they are crossed with
severe combined immunodeficiency (SCID) mice [20], or
with mice that are nullizygous for the cell cycle inhibitor
p21 [21]. Preliminary analysis of mammary development in
TGF-b1
–/– SCID mice shows a dramatic reduction in
ductal complexity, suggesting an essential role for TGF-b1
in ductal outgrowth (Ingman WV, Robertson SA, personal
communication). Interestingly, on the p21–/– background,
TGF-b1
+/– mice (in which TGF-b1 concentrations are sig-
nificantly reduced) show accelerated mammary develop-
ment [10]. TGF-b3-null mutant mice also die at birth, but
transplantation of their rudimentary mammary glands into
recipient SCID mice allowed mammary development to be
assessed. This did not reveal any gross defects in branch-
ing morphogenesis, however, and the glands apparently
developed normally through to lactation [12].
At first sight these results on the mammary gland devel-
opment of TGF-b1-null and TGF-b3-null mutant mice are
difficult to reconcile with the experiments described
above suggesting inhibitory roles for TGF-bs in the
branching morphogenesis of this organ. However, in cul-
tures of TAC-2.1 mammary cells, low concentrations of
TGF-b1 had a positive effect on tubule and branching for-
mation that was coincident with the inhibition of colony
formation, whereas high concentrations only inhibited
colony formation and had no effect on morphogenesis.
Low concentrations also stimulated cell proliferation,
whereas high doses inhibited this parameter, an effect
Available online http://breast-cancer-research.com/content/3/4/230
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Table 1
Genetic analysis of TGF-b b and HGF/SF function in the mammary gland
Experimental design Cell type expression*/tissue affected† Phenotype Reference
Gain of function
MMTV-TGF-b1 Mammary epithelium Inhibition of ductal development [15]
WAP-TGF-b1 Lobuloalveolar progenitors and cells Inhibition of alveolar development;  [17]
aging of stem cells
b-lactoglobulin- TGF-b3 Alveolar and ductal epithelial cells during  Induction of apoptosis [12]
lactation
Retroviral HGF Primary mammary epithelial cells  Increased TEB number and branching [32]
transplanted into the mammary fat pad
Loss of function
MMTV-dnTGF-b receptor II Mammary epithelium Precocious lobuloalveolar development  [18]
and milk production
MMTV-dnTGF-b receptor II Mammary stroma Increased lateral branching [13]
TGF-b1
–/– SCID Whole animal Hypoplastic ductal tree Ingram W, Robertson SA, 
personal communication
TGF-b1
+/– p21—/— Whole animal Accelerated mammary development;  [10]
normal adult structure
SMAD-3—/— Whole animal Hypoplastic mammary epithelium [21]
TGF-b3
—/— Mammary epithelium into wild-type stroma Reduced apoptosis during involution.  [12]
Normal mammary development
dnMet Mammary tumor cells in culture followed  Increased tubule formation [30]
by transplantation to mice
*For gain of function. †For loss of function. dn, dominant negative. MMTV, mouse mammary tumor virus; WAP = whey acidic protein.that was dependent on the extracellular matrix [22]. Thus,
TGF-bs might promote the outgrowth of TEBs and lateral
branches at low concentration, whereas higher concen-
trations suppress growth in terminal end ducts and along
the ductal length, perhaps by inhibiting expression or
action of HGF/SF, as has been reported in culture [23]
(Fig. 2). These conclusions would be consistent with the
opposite effects on mammary development observed in
mice with one or two mutant alleles of TGF-b1. Confirma-
tion of this interpretation will await detailed studies on the
mammary glands of the homozygous and heterozygous
mutants. This by necessity will involve mammary gland
transplantation in order to confirm that the effects of the
mutations are organ autonomous.
Toward the end of pregnancy TGF-b expression is dramat-
ically downregulated, with very low levels of TGF-b2
mRNA detected during lactation [9,11,12]. Milk protein
expression by mammary epithelial cells in culture, in
response to lactogenic hormones, is suppressed by
TGF-b1 [24,25]. Expression of a TGF-b receptor II domi-
nant-negative transgene in the mammary epithelium
resulted in premature expression of casein [18]. These
results, together with those regarding over-expression of
TGF-b1 from the whey acidic protein promoter (Table 1)
[18], suggest that another role for TGF-bs is to regulate
lobuloalveolar development and suppress milk production
during pregnancy. These effects are alleviated by down-
regulation of these proteins toward the end of pregnancy,
such that the full development of the mammary gland
during lactation is permitted (Fig. 2).
Immediately after weaning, expression of TGF-b3 is dra-
matically induced in the alveolar epithelium in a pattern
that precedes the onset of apoptosis and that persists for
several days at a lower, but still significant level [11,12].
Transgenic over-expression of TGF-b3 during lactation
induced alveolar epithelial apoptosis without causing
gland involution. TGF-b3-null mutant mammary epithelial
tissue transplanted into the cleared fat pad of a wild-type
recipient developed and underwent lactation, but on
weaning the tissue showed a lower rate of apoptosis than
that in wild-type control tissue, but without a complete
ablation of this response. Analysis of SMAD-4 nuclear
association indicated that the alveolar epithelium was the
target for TGF-b3 acting through an autocrine mechanism.
This induction of TGF-b3 was in response to milk stasis
rather than changes in the hormonal milieu. Together the
data provide compelling evidence that TGF-b3 is one of
the mammary-derived signals that induce apoptosis during
the first phase of involution [12] (Fig. 2).
Hepatocyte growth factor/scatter factor
HGF/SF, originally identified by its motogenic activity on
cultured cells, is a pleiotropic cytokine that promotes sur-
vival and proliferation in a wide variety of cells. It also has
dramatic effects on cell morphology, triggering intrinsic
morphogenic events such as tubule formation in many
epithelial cell lines, including those from the mammary
gland. It binds to and signals through a unique transmem-
brane tyrosine kinase receptor, the product of the c-met
proto-oncogene. In general, the c-met oncogene is
expressed in epithelial cells, whereas the ligand is
expressed in the surrounding mesenchyme, providing a
mechanism for the epithelial–mesenchymal inductive
processes during development. HGF/SF receptor signals
in large part via the ras signaling pathway initially after
binding the docking protein Grb2, which is essential for c-
met signaling [26]. HGF/SF also binds to the extracellular
matrix, and heparan sulfate proteoglycans potentiate
HGF/SF signaling [27].
Breast Cancer Research    Vol 3 No 4 Pollard
Figure 2
Postulated roles for TGF-b and HGF/SF during the life cycle of the
mammary gland. TGF-bs have complex roles during mammary
development, according to their concentration. Although most of the
experimental evidence points to inhibition of ductal branching,
preliminary analysis of both TGF-b1- and SMAD-3-null mutant mice
suggest a requirement for TGF-b1 for mammary development. Thus,
TGF-bs have both concentration- and context-dependent effects on
mammary gland development. HGF/SF promotes ductal outgrowth
through an integrin-mediated process. This action is inhibited by
TGF-b1, indicating that interactions between these growth factors play
a role in ductal spacing as the mammary gland grows out over the fat
pad. During pregnancy, TGF-bs appear to inhibit alveolar development
and suppress milk formation. The decline in TGF-b expression at the
end of pregnancy appears to be necessary for full lobuloalveolar
development and lactation. After weaning involution is begun, with
TGF-b3 inducing apoptosis in the lobuloalveolar structures through an
autocrine mechanism. Ductal morphogenesis and branching of the resultant
tubules can be induced by HGF/SF in primary and certain
established mammary epithelial cells cultured in collagen
gels or matrigel [23,28,29]. Expression of a dominant-
negative c-met receptor can also reverse the tumorigenic
phenotype of DN-DA3 mouse mammary adenocarcinoma
cell line after transplantation into nude mice, causing them
to adopt a differentiated phenotype that is characterized
by extensive tubule formation [30]. HGF/SF is synthesized
in the mammary stroma, probably by fibroblasts, and acts
on receptor-expressing ductal epithelial cells [23].
Together these experiments strongly suggest that
HGF/SF c-met signaling is a classical epithelial–mes-
enchymal inductive pathway that is important for ductal
morphogenesis in the mammary gland (Fig. 2). Despite
their dramatic nature, however, a caveat of the culture
experiments is that the cells form unilaminar tubes that do
not resemble the elaborate TEBs that are the primary
growth point and determinant of branching in the develop-
ing mammary gland.
Unfortunately, null mutants in both HGF/SF and c-met
genes in mice cause embryonic lethality because of pla-
cental insufficiency and developmental defects in the liver
and muscle [31]. Over-expression of HGF/SF or c-met in
the mammary epithelium resulted in hyperplasia and
tumorigenesis, but the effects on early mammary develop-
ment were not assessed [23]. In order to overcome these
problems, Yant et al [32] transfected primary mouse
mammary epithelial cells with a retrovirus containing
HGF/SF cDNA, and transplanted these into a cleared
recipient fat pad. This increased TEB size and number,
and resulted in a hyperplastic ductal tree. These data are
consistent with a positive role for HGF/SF in ductal
morphogenesis (Fig. 2).
Conclusion
The exquisitely branched structure of the mammary gland
requires sophisticated positional clues to maintain ductal
spacing. TEBs, with their unique club-shaped multilaminar
structures, are both the growth and branching decision
points for the developing mammary gland in mice. These
structures are encased in a basement membrane, and
during their growth they recruit around their body a unique
stroma that includes macrophages, eosinophils, and
fibroblasts. Unexpectedly, both macrophages and
eosinophils appear to regulate ductal morphogenesis,
because this process is inhibited in mouse mutants that
reduce the abundance of these cells in the mammary
gland [3]. Interestingly, macrophages can both produce
and respond to TGF-bs, suggesting that these migratory
cells could locally and transiently modify the responsive-
ness of the tissue to these factors. For example, TGF-b1
inhibits cytokine induction of matrix metalloproteinase-12
in macrophages [33], possibly limiting their ability to
remodel matrix and thereby suppressing lateral branching.
Furthermore, macrophages have been shown to activate
LTGF-b1 following binding to cell surface expressed b-
glycan [34]. Thus, it may be speculated that at least part
of the role of macrophages in regulating branching mor-
phogenesis is to activate epithelial cell-derived TGF-b1
and, in turn, to have their remodeling functions modified by
TGF-b1 in a very precise pattern. This is consistent with
the role of TGF-b1 in matrix remodeling after radiation-
induced damage of the mammary gland [35].
The epithelial cells of the TEBs also need to migrate
through the stroma as they grow out across the fat pad.
TGF-b1 can also reversibly induce trans-differentiation of
mammary epithelial cells to mesenchyme-like cells that
may be important in the migration of cells during TEB out-
growth [36]. Perturbation of b1-integrin signaling by block-
ing antibodies affects TEB formation and inhibits
mammary gland development [37]. Anti-b1-integrin anti-
bodies blocked HGF/SF-induced tubulogenesis in cul-
tures of mammary epithelial cells, suggesting that HGF/SF
signals to the integrin pathways to promote cellular adhe-
sion during ductal morphogenesis [37]. A major effect of
TGF-bs is to modulate matrix deposition by fibroblasts,
cells that are found around the TEB. This suggests that
TGF-bs and HGF/SF may co-operate in the regulation of
the migration of epithelial cells across the fatty stroma by
altering integrin–matrix signaling locally. Furthermore, in
other tissues TGF-bs play an important role in angiogene-
sis [38], a process that is assumed to be essential for
ductal outgrowth and necessary for mammary gland func-
tion. Thus, it is likely that TGF-bs locally regulate angio-
genesis to accommodate the developing mammary gland.
In addition to these effects of TGF-bs on the stroma, at
probably higher concentrations TGF-bs inhibit ductal devel-
opment through their cell cycle inhibitory effects on epithe-
lial cells. There is considerable understanding, particularly
in mammary epithelial cells in culture, of the intracellular
pathways that mediate the growth inhibitory properties of
TGF-b1. TGF-b1 maintains the retinoblastoma protein in its
cell cycle inhibitory hypophosphorylated state through the
induction of the cyclin-dependent inhibitors p15ink4b and
p21cipl/waf1 and the downregulation of cyclin-dependent
kinase 2 phosphatase cdc25A [4]. The early signal trans-
duction pathways via SMAD-2, -3, and -4 are also well
documented [4]. In contrast, HGF/SF promotes epithelial
cellular proliferation and ductal outgrowth in culture. Its
signal transduction pathway through the c-met receptor
has also been well studied [31]. In fact, a downstream
kinase target, Gab1, of this receptor mimicked the action of
HGF/SF on tubule formation when transfected into cul-
tured EpH4 mouse mammary epithelial cells [28].
Most of this information on HGF/SF and TGF-b signal
transduction has been derived from cells in culture,
however, and has not been extrapolated to, or confirmed
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therefore be obtained by analysis of these signaling path-
ways in the mammary gland during development. This is
especially important given the multiple levels of control
over TGF-b and HGF action. It is essential to define sites
of TGF-b1 and HGF/SF signaling. A powerful tool in this
approach will be use of the immunolocalization of nuclear
SMAD-4 and of antiphosphorylation specific anti-c-met
antibodies as surrogate markers within cells for TGF-b
receptor and c-met activation, respectively. These studies
could help define the temporal and spatial requirements in
different cell types throughout the development of the
mammary gland. Similarly, conditional ablation of specific
signaling molecules in particular cell types in the mammary
gland could reveal individual functions for these growth
factors. Allelic series of mutants can also reveal differential
functions, as was elegantly shown for oncogenic signaling
during mammary gland cancer [39] and for the role of the
Grb2 binding site on the c-met receptor that was specifi-
cally required for its function in muscle, but not placental
or liver development [31].
HGF/SF and TGF-bs appear to have important roles in
branching morphogenesis, lobuloalveolar development,
and involution in mice. Similar expression patterns in other
species, including human, argue for similar roles in these
organisms [40,41]. These growth factors integrate within
a complex web of growth factor and hormone signaling to
pattern the ductal tree. These include other members of
the TGF-b family, such as activins and inhibins [1], as well
as other growth factors that influence mammary gland
development, such as insulin-like growth factor-1, which
has also recently been shown to modulate TGF-b1 expres-
sion in this organ [42]. The complexity of the responses
and the multiple levels of regulation, including the pres-
ence of latent forms and extracellular binding proteins,
suggest that cell culture experiments will be inadequate to
tease out the different roles for these proteins. Only
sophisticated genetic experiments in vivo, coupled with
the unique ability of the mammary gland elements to be
transplanted between genotypes, can provide causality for
the involvement of TGF-bs and HGF/SF in different
aspects of mammary gland morphogenesis and function.
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